Experience

InnoCare and KeyMed Jointly Announce License Agreement With Prolium

January 20, 2025

Cooley represented Beijing Tiannuo Jiancheng Pharmaceutical Technology, a joint venture of a subsidiary of InnoCare Pharma (HKEX: 09969; SSE: 688428) and a subsidiary of KeyMed Biosciences (HKEX: 02162), in connection with a joint exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02 (CM355), a CD20xCD3 bispecific antibody.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Freddy Yip
Associate, Hong Kong
Michael Shen
Special Counsel, Shanghai
Ivy Wang
Associate, Shanghai
Letian Wei
Legal Consultant, Shanghai
Jameson Davis
Associate, Boston
Robert Eisenbach
Of Counsel, San Francisco
Xander Lee
Partner, Santa Monica
Bin Wang
Special Counsel, Palo Alto
Monica Xu
Special Counsel, Shanghai

Related Practices & Industries

Angitia Biopharmaceuticals Announces $120 Million Series C

December 17, 2024

Cooley advised Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, on its $120 million Series C.

Read more

Related contacts

Patrick Loofbourrow
Partner, Singapore
Monica Xu
Special Counsel, Shanghai
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Chadwick Mills
Partner, San Francisco
Charlie Kim
Partner, San Diego
Ivy Wang
Associate, Shanghai
Letian Wei
Legal Consultant, Shanghai
Brandon Lefebvre
Quantitative Analyst, Boston

Related Practices & Industries

Chimagen Biosciences Announces Sale of CMG1A46 to GSK

October 29, 2024

Cooley advised Chimagen Biosciences, a privately held biotechnology company, on its agreement to sell CMG1A46, a clinical-stage dual CD19 and CD20-targeted T-cell engager (TCE), to GSK, a global biopharma company, for an upfront payment of $300 million, plus success-based development and commercial milestone payments totaling up to $550 million.

Read more

Related contacts

Marya Postner
Partner, Palo Alto
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Zack Gong
Associate, Shanghai
Jenny Ge
Associate, Santa Monica
Monica Xu
Special Counsel, Shanghai
Christopher Kimball
Partner, Washington, DC
Rama Padmanabhan
Partner, San Diego
Aaron Pomeroy
Partner, Colorado
Jonathan Rivinus
Partner, Colorado
Rachel Thorn
Of counsel, New York
David Wilson
Partner, London
David Burns
Special Counsel, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Bin Wang
Special Counsel, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Robert Eisenbach
Of Counsel, San Francisco
Natasha Leskovsek
Of Counsel, Washington, DC
Eerik Kukebal
Associate, London
Amanda Pacheco
Associate, Palo Alto
Leo Spicer-Phelps
Partner, London
Lunga Su
Associate, Shanghai
Ivy Wang
Associate, Shanghai
Zhijing Yu
Associate, Singapore
Letian Wei
Legal Consultant, Shanghai

Related Practices & Industries

Jiangsu Hengrui Pharmaceuticals Out-Licenses GLP-1 Portfolio

May 17, 2024

Cooley advised Jiangsu Hengrui Pharmaceuticals, one of the largest pharmaceutical companies in China, on its licensing of global rights (excluding Greater China) for the development, production and commercialization of three of its proprietary glucagon-like peptide-1 (GLP-1) drugs to Hercules CM Newco, a newly established Delaware company.

Read more

Related contacts

Sharon Connaughton
Special Counsel, Washington, DC
Annie Froehlich
Partner, Washington, DC
Zack Gong
Associate, Shanghai
Kevin King
Partner, Washington, DC
Edmond Lay
Partner, San Diego
Howard Morse
Senior Counsel, Washington, DC
Sarah Oliai
Associate, Washington, DC
W. Chad Shear
Partner, San Diego
Michael Shen
Special Counsel, Shanghai
Alan W. Tamarelli
Partner, New York
Karen Tsai
Special Counsel, Washington, DC
Ivy Wang
Associate, Shanghai
Bin Wang
Special Counsel, Palo Alto
Letian Wei
Legal Consultant, Shanghai
Joanna Zhang
Associate, San Diego

Related Practices & Industries

ProfoundBio Announces $1.8 Billion Acquisition by Genmab

April 3, 2024

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.

Read more

Related contacts

Rama Padmanabhan
Partner, San Diego
Patrick Loofbourrow
Partner, Singapore
Rowook Park
Partner, San Diego
Ruomu Li
Partner, Shanghai
Jenny Ge
Associate, Santa Monica
Ross Eberly
Partner, Santa Monica
Megan Browdie
Partner, Washington, DC
Christopher Kimball
Partner, Washington, DC
Xander Lee
Partner, Santa Monica
Jamie Leigh
Partner, San Francisco
Izzy Lubarsky
Partner, New York
Barbara Mirza
Partner, Santa Monica
Sonia Nath
Partner, Washington, DC
Jean Park
Partner, New York
Stacey A. Bradford
Special Counsel, Washington, DC
Jeff Goldman
Special Counsel, Palo Alto
Amy Hallman Rice
Special Counsel, San Diego
Karen Tsai
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Julia R. Brinton
Special Counsel, Washington, DC
Megan Drill
Associate, San Diego
Mari Dugas
Associate, Washington, DC
Allison Kutner
Associate, New York
Jiqiang Lin
Associate, New York
Tyler Saavedra-Buckley
Associate, San Francisco
Patrick Sharma
Associate, Santa Monica
Ivy Wang
Associate, Shanghai
Monica Xu
Special Counsel, Shanghai
Freddy Yip
Associate, Hong Kong
Zhijing Yu
Associate, Singapore
Andy Zachrich
Associate, San Francisco
Letian Wei
Legal Consultant, Shanghai

Related Practices & Industries

Admissions and credentials

New York

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.